antivir
drug
influenza
viru
play
import
role
treatment
prevent
human
influenza
infect
adamantan
use
decad
resist
class
drug
becom
preval
part
world
neuraminidas
inhibitor
oseltamivir
current
regard
first
line
defenc
pandem
suitabl
vaccin
produc
suffici
quantiti
emerg
resist
drug
human
influenza
virus
well
subtyp
vietnam
thu
caus
concern
resist
report
zanamivir
anoth
neuraminidas
inhibitor
expand
rang
antivir
drug
effect
inhibit
influenza
viru
replic
thu
matter
urgenc
recent
review
suggest
antimalari
drug
chloroquin
may
antivir
activ
lysosomotrop
weak
base
impair
replic
virus
reduc
effici
endosomemedi
viru
entri
inhibit
lowph
depend
proteas
transgolgi
vesicl
antivir
activ
human
immunodefici
viru
hiv
sar
coronaviru
demonstr
previous
chloroquin
use
studi
influenza
viru
replic
vitro
howev
mm
concentr
use
high
indic
therapeut
use
thu
carri
vitro
antivir
assay
determin
inhibitori
concentr
respect
chloroquin
influenza
viru
subtyp
vitro
antivir
screen
assay
modifi
previous
describ
method
carri
triplic
influenza
virus
atcc
atcc
use
studi
briefli
serial
dilut
chloroquin
incub
overnight
mdck
cell
give
final
cell
count
cell
per
well
microtitr
plate
nunc
roskild
denmark
drug
equilibr
cell
viru
concentr
tissu
cultur
infect
dose
ad
well
plate
incub
day
viral
replic
assess
method
realtim
rtpcr
use
previous
describ
protocol
carri
nucleic
acid
extract
supernat
cultur
use
roch
lightcycl
system
roch
diagnost
mannheim
germani
fitclabel
antinucleoprotein
monoclon
antibodi
chemicon
intern
temecula
ca
use
stain
remain
cell
monolay
view
ultraviolet
light
microscop
control
consist
viru
cell
cell
viru
serial
dilut
amantadin
place
chloroquin
includ
plate
cytotox
drug
also
assess
concentr
use
antivir
assay
result
shown
tabl
see
addit
file
cellular
toxic
observ
chloroquin
concentr
higher
dilut
complet
inhibit
influenza
viru
replic
observ
chloroquin
evid
microscop
absenc
immunofluoresc
focu
well
similar
ct
valu
realtim
rtpcr
viru
control
number
fluoresc
foci
increas
decreas
concentr
chloroquin
similarli
reflect
decreas
ct
valu
real
time
rtpcr
respect
supernat
chloroquin
respect
respect
hand
drug
abl
inhibit
influenza
viru
replic
increas
preval
resist
drug
demand
newer
class
antiinfluenza
drug
although
new
compound
still
develop
antiinfluenza
activ
assess
may
take
year
fulfil
regulatori
requir
clinic
use
initi
altern
mode
drug
discoveri
may
find
new
use
old
drug
avail
extens
experi
clinic
use
may
shorten
durat
need
variou
phase
clinic
trial
chloroquin
serv
exampl
result
suggest
chloroquin
clinic
use
inhibitori
activ
influenza
viru
replic
virus
lower
plasma
concentr
chloroquin
attain
dosag
use
prophylaxi
treatment
acut
malaria
suggest
dosag
need
inhibit
human
influenza
viru
replic
well
toler
patient
ad
effect
chloroquin
immunomodulatori
activ
may
ad
benefit
treatment
influenza
infect
sinc
patholog
avian
influenza
infect
human
appear
mediat
proinflammatori
cytokin
although
shown
chloroquin
abl
inhibit
two
refer
subtyp
influenza
virus
test
suscept
wide
rang
clinic
isol
influenza
virus
chloroquin
well
vivo
studi
would
need
determin
role
chloroquin
prophylaxi
treatment
influenza
infect
would
also
interest
determin
activ
chloroquin
highli
pathogen
subtyp
would
add
limit
antivir
stockpil
possibl
pandem
conclus
chloroquin
demonstr
inhibitori
effect
replic
human
influenza
viru
vitro
studi
explor
therapeut
prophylact
potenti
influenza
epidem
pandem
encourag
tissu
cultur
infect
dose
concentr
chloroquin
need
inhibit
viral
growth
concentr
chloroquin
need
inhibit
viral
growth
rtpcr
reversetranscript
polymeras
chain
reaction
ifa
immunofluoresc
assay
author
declar
compet
interest
eeo
design
studi
wrote
manuscript
jswc
carri
realtim
rtpcr
jpl
set
valid
realtim
rtpcr
influenza
laboratori
rcsc
carri
viru
cultur
antivir
assay
ifa
